TransMedics short interest high
TransMedics ($TMDX) shows roughly 26% of its float shorted even as the stock trades on high forward multiples — a snapshot analysts flagged as an opportunity for competitive medtech research. Elevated short interest can mean high conviction disagreements about growth and multiples in the sector. (x.com)
Finviz's live snapshot shows a 25.18% short float for TMDX with about 8.33 million shares sold short and a short-ratio (days to cover) of 10.0 as of the March 25, 2026 quote. (finviz.com) Benzinga's short-interest table recorded 36.14% of the public float sold short with a settlement date of December 31, 2025 and an 11.38 days-to-cover figure, highlighting reporting-date variation across sources. (benzinga.com) MarketBeat reported a 21.59% short interest as of the November 14, 2025 report and listed an 8.7 short-interest ratio, underscoring that short metrics have shifted materially within the last several months. (marketbeat.com) Valuation screens put TransMedics at premium multiples: Finviz lists a forward P/E near 28.60, a price/sales ratio around 5.96, a market cap roughly $3.6 billion, and trailing sales near $605.5 million. (finviz.com) Management issued 2026 revenue guidance of about $727 million to $757 million alongside 2025 results, a range analysts have used to justify both upward price-target revisions and caution on sustainment of growth. (sahmcapital.com) On Feb. 25, Oppenheimer and Needham raised price targets (to $175 and $174 respectively) while broader consensus price targets aggregated near $152, reflecting divergent analyst views on growth versus valuation. (marketscreener.com) Some desk notes and coverage changes have cited increasing competitive pressure and potential deceleration as reasons for cooling conviction, a dynamic that helps explain why short interest and analyst stances remain polarized. (m.uk.investing.com)
